<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03049540</url>
  </required_header>
  <id_info>
    <org_study_id>V1 2016-10-12</org_study_id>
    <nct_id>NCT03049540</nct_id>
  </id_info>
  <brief_title>Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function</brief_title>
  <acronym>SERVE</acronym>
  <official_title>Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss National Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses in a double-blind, randomized, placebo-controlled multi-center pilot
      trial the effect of PDE-5 inhibition with Tadalafil on right ventricle size and function,
      exercise capacity and neurohumoral activation in adults with congenital heart disease and a
      right ventricle in subaortic position over a 3-year follow-up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there are an estimated 300-600 adults living in Switzerland with congenital heart
      disease (CHD) and a right ventricle (RV) in subaortic (systemic) position. This includes
      adults with prior atrial switch operations for complete transposition of the great arteries
      (D-TGA) and adults with congenitally corrected transposition of the great arteries (ccTGA).
      Although midterm survival is favourable, late outcome is compromised by ventricular
      dysfunction of the systemic RV, end-stage heart failure, and premature death. Medical heart
      failure therapy (ACE-inhibitors, beta-blockers, aldosterone antagonists) has been shown to
      improve ventricular function and survival in patients with left heart failure from acquired
      heart disease. Unfortunately, case-reports and studies failed to show similar clinical
      benefits of these drugs in adults with a failing systemic RV. Currently, the only established
      end-stage therapy for a failing systemic RV is heart transplantation. Given the ubiquitous
      shortage of donor organs and the number of adults at risk, medical options to improve the
      fate of patients with a systemic RV are urgently needed.

      The RV and left ventricle (LV) have different embryological origins, myocardial architecture
      and contractile properties. In response to increased afterload, as in an RV in systemic
      position, the RV expresses a fetal gene pattern, with an increase in phosphodiesterase
      (PDE)-5 expression. PDE-5 is not expressed in the normal RV, but is up-regulated in the
      hypertrophied RV. PDE-5 inhibition increases contractility in experimental models of RV
      hypertrophy, but not in the normal RV. In clinical practice, the effects of PDE-5 inhibition
      on systemic RV function and exercise capacity in adults with TGA have not been tested.

      This study assesses in a double-blind, randomized, placebo-controlled multi-center pilot
      trial the effect of PDE-5 inhibition with Tadalafil on RV size and function, exercise
      capacity and neurohumoral activation in adults with a systemic RV over a 3-year follow-up
      period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2017</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic right ventricle endsystolic volume</measure>
    <time_frame>3 years</time_frame>
    <description>Assess of the improvement of Tadalafil on systemic right ventricle endsystolic volume measured by cardiovascular magnetic resonance imaging (CMR) or cardiac multirow detector computed tomography (CMDCT) in patients with contraindications for cardiac MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic right ventricle ejection fraction</measure>
    <time_frame>3 years</time_frame>
    <description>Systemic right ventricle ejection fraction measured by CMR or CMDCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiopulmonary exercise capacity</measure>
    <time_frame>3 years</time_frame>
    <description>Assess the effects of PDE-5 inhibition on cardiopulmonary exercise capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum neurohormonal activation</measure>
    <time_frame>3 years</time_frame>
    <description>Assess the effects of PDE-5 inhibition on serum neurohormonal activation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Heart Defects, Congenital</condition>
  <condition>Transposition of Great Vessels With Ventricular Inversion</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tadalafil 20 MG, p.o., once per day for 3 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 20 MG, p.o., once per day for 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil 20 MG</intervention_name>
    <description>Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil</description>
    <arm_group_label>Tadalafil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 20 MG</intervention_name>
    <description>Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Systemic right ventricle due to prior atrial switch operations for complete transposition
        of the great arteries (D-TGA) due to congenitally corrected transposition of the great
        arteries (ccTGA).

        Exclusion Criteria:

          -  Incapability of giving informed consent

          -  Myocardial infarction, stroke, or open heart surgery within the 3 months prior to
             baseline visit

          -  Expected heart transplant within the next 6 months starting from baseline

          -  Pregnant or nursing women (a pregnancy test is mandatory prior to randomization; women
             of childbearing potential must agree to use reliable contraception from randomization
             to end of study treatment)

          -  Severe renal insufficiency (Creatinine clearance ≤ 30 ml/min)

          -  Severe hepatic insufficiency (Child-Pugh-Class C)

          -  Hypotension with blood pressures &lt; 90/50 mmHg at the baseline visit

          -  Hypersensibility to Tadalafil

          -  Allergy to iodinated (in patients undergoing CMDCT) or Gadolinium-based (in patients
             undergoing CMR) contrast agents.

          -  Co-medication with nitrates

          -  Regular use of &quot;poppers&quot;, i.e. alkyl nitrites, that are inhaled for recreational
             purposes, including as club drugs used at dance clubs.

          -  Co-medication with potent CYP3A4 inhibitors: Ketoconazole, Ritonavir, Rifampicin

          -  Co-medication with other PDE-5 inhibitors for erectile dysfunction during the last
             four weeks prior to baseline visit

          -  Medical history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

          -  Hereditary Galactose intolerance, Lactase deficiency or
             Glucose-Galactose-Malabsorption

          -  Participation at another clinical trial in which the primary endpoint has not been
             reached.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schwerzmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bern University Hospital, Zentrum fuer angeborene Herzfehler</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Schwerzmann, MD</last_name>
    <phone>+41316320099</phone>
    <email>markus.schwerzmann@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin II, Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harald Gabriel, MD</last_name>
      <phone>+43-(0)1-40400-62800</phone>
      <email>Harald.Gabriel@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Harald Gabriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologie Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Tobler, MD</last_name>
      <phone>+41 61 265 52 14</phone>
      <email>Daniel.Tobler@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Tobler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schwerzmann, MD</last_name>
      <phone>+41 31 632 00 99</phone>
      <email>markus.schwerzmann@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Markus Schwerzmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabienne Schwitz</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kerstin Wustmann</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Geneve</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Bouchardy, MD</last_name>
      <phone>+41 22 372 75 31</phone>
      <email>judith.bouchardy@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Judith Bouchardy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Bouchardy, MD</last_name>
      <phone>+41 79 556 54 67</phone>
      <email>Judith.bouchardy@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Judith Bouchardy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reto Engel, MD</last_name>
      <phone>+41 71 494 10 51 / 12 48</phone>
      <email>Reto.Engel@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Reto Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich, Universitäres Herzzentrum</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Greutmann, MD</last_name>
      <phone>+41 44 255 38 83</phone>
      <email>Matthias.Greutmann@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Greutmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, McGhie J, Bos E, Bogers AJ, Simoons ML. Decline in ventricular function and clinical condition after Mustard repair for transposition of the great arteries (a prospective study of 22-29 years). Eur Heart J. 2004 Jul;25(14):1264-70.</citation>
    <PMID>15246646</PMID>
  </reference>
  <results_reference>
    <citation>van der Bom T, Bouma BJ, Meijboom FJ, Zwinderman AH, Mulder BJ. The prevalence of adult congenital heart disease, results from a systematic review and evidence based calculation. Am Heart J. 2012 Oct;164(4):568-75. doi: 10.1016/j.ahj.2012.07.023. Review.</citation>
    <PMID>23067916</PMID>
  </results_reference>
  <results_reference>
    <citation>Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L. Congenital heart disease in the general population: changing prevalence and age distribution. Circulation. 2007 Jan 16;115(2):163-72. Epub 2007 Jan 8.</citation>
    <PMID>17210844</PMID>
  </results_reference>
  <results_reference>
    <citation>Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A. Specialized adult congenital heart disease care: the impact of policy on mortality. Circulation. 2014 May 6;129(18):1804-12. doi: 10.1161/CIRCULATIONAHA.113.005817. Epub 2014 Mar 3.</citation>
    <PMID>24589851</PMID>
  </results_reference>
  <results_reference>
    <citation>Cuypers JA, Eindhoven JA, Slager MA, Opić P, Utens EM, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos D, Meijboom FJ, Bogers AJ, Roos-Hesselink JW. The natural and unnatural history of the Mustard procedure: long-term outcome up to 40 years. Eur Heart J. 2014 Jul 1;35(25):1666-74. doi: 10.1093/eurheartj/ehu102. Epub 2014 Mar 18.</citation>
    <PMID>24644309</PMID>
  </results_reference>
  <results_reference>
    <citation>Vejlstrup N, Sørensen K, Mattsson E, Thilén U, Kvidal P, Johansson B, Iversen K, Søndergaard L, Dellborg M, Eriksson P. Long-Term Outcome of Mustard/Senning Correction for Transposition of the Great Arteries in Sweden and Denmark. Circulation. 2015 Aug 25;132(8):633-8. doi: 10.1161/CIRCULATIONAHA.114.010770. Epub 2015 Jul 16.</citation>
    <PMID>26185211</PMID>
  </results_reference>
  <results_reference>
    <citation>Roche SL, Redington AN. The failing right ventricle in congenital heart disease. Can J Cardiol. 2013 Jul;29(7):768-78. doi: 10.1016/j.cjca.2013.04.018. Review.</citation>
    <PMID>23790549</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Bom T, Winter MM, Bouma BJ, Groenink M, Vliegen HW, Pieper PG, van Dijk AP, Sieswerda GT, Roos-Hesselink JW, Zwinderman AH, Mulder BJ. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013 Jan 22;127(3):322-30. doi: 10.1161/CIRCULATIONAHA.112.135392. Epub 2012 Dec 17.</citation>
    <PMID>23247302</PMID>
  </results_reference>
  <results_reference>
    <citation>Dos L, Pujadas S, Estruch M, Mas A, Ferreira-González I, Pijuan A, Serra R, Ordóñez-Llanos J, Subirana M, Pons-Lladó G, Marsal JR, García-Dorado D, Casaldàliga J. Eplerenone in systemic right ventricle: double blind randomized clinical trial. The evedes study. Int J Cardiol. 2013 Oct 15;168(6):5167-73. doi: 10.1016/j.ijcard.2013.07.163. Epub 2013 Jul 25.</citation>
    <PMID>23972966</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 Jul 17;116(3):238-48. Epub 2007 Jul 2.</citation>
    <PMID>17606845</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012 Jan 3;59(1):9-15. doi: 10.1016/j.jacc.2011.07.051. Review.</citation>
    <PMID>22192662</PMID>
  </results_reference>
  <results_reference>
    <citation>Kloner RA, Jackson G, Hutter AM, Mittleman MA, Chan M, Warner MR, Costigan TM, Vail GM. Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. Am J Cardiol. 2006 Jun 15;97(12):1778-84. Epub 2006 Apr 27.</citation>
    <PMID>16765134</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2017</study_first_submitted>
  <study_first_submitted_qc>February 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2017</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

